No Breathing Room For Advair: GSK Combo Part Of Asthma Drug Restrictions
Executive Summary
GlaxoSmithKline's asthma combination product Advair is included in an FDA advisory against first-line use of long-acting beta agonist bronchodilators despite an advisory committee review that suggested Advair was less risky than other products
You may also be interested in...
FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs
FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28
FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs
FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28
NIH Asthma Guide Concurs With FDA In Supporting LABAs For Adjunctive Use
Sales of combination inhaled corticosteroid/long-acting beta2-agonists may receive a boost from NIH guidelines endorsing their use as adjunctive therapy in certain asthma patients